Molecular Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2024-09-22 Dr医小小生来自上海

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤微环境;肿瘤
经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2024-03-10 1811e984f8m 来自安徽省

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;肿瘤化疗
经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。

178 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2023-10-20 ms1000001749825166 来自江苏省

很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。

103 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2022-01-21 DDPP

评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。

127 21

展开21条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2022-08-02 ms6000001160390657

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：lncRNA
经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊

155 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2023-10-26 ms4000001583479348 来自北京

终于接收啦历经四个月。希望杂志越来越好吧。

124 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2024-01-21 ms9000001581615796 来自江苏省

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修

123 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2024-07-03 ms6000000084807408 来自甘肃省

偏重的研究方向：肿瘤神经生物学
经验分享：7.1投了一篇综述，在这里记录一下投稿过程

83 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2024-03-19 ms7000000762441132 来自河南省

审稿速度:3.0
偏重的研究方向：cancer
经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers.

102 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤微环境;肿瘤 经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省)]

2023-11-12 wym0577 来自浙江省

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？

0 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务